{'fraction_non_alphanumeric': 0.042293233082706765, 'fraction_numerical': 0.04755639097744361, 'mean_word_length': 4.945251396648045, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents

Nursing home residents often fail to mount robust responses to vaccinations and recent reports of breakthrough infections, particularly from variants of concern, raise questions about whether vaccination regimens elicit a sufficient humoral immune response or if booster doses are warranted. We examined SARS-CoV-2 antibody levels and neutralizing capacity in nursing home residents 3-5 months after 2 doses of mRNA-1273 or BNT163b2 vaccination as per recommended schedules.Nursing home residents were recruited from eight long-term care homes in Ontario, Canada, between March and July 2021. Antibody levels and neutralization capacity from a previously published convalescent cohort were used as a comparator. Serum SARS-CoV-2 IgA/G/M against spike (S) protein and its receptor-binding domain (RBD) were measured by validated ELISA, with assay cut-off at the mean and 3 standard deviations of a pre-COVID-19 population from the same geographic region. Antibody neutralization was measured against the wild-type strain of SARS-CoV-2 and the beta variant of concern (B.1.351).No neutralizing antibodies were detected in ∼20% of residents to the wild-type virus (30/155; 19%) or beta variant (27/134; 20%). Residents that received BNT163b2 had a ∼4-fold reduction in neutralization to the wild-type strain, and a ∼2-fold reduction in neutralization to the beta variant relative to those who received mRNA-1273.Current mRNA SARS-CoV-2 vaccine regimens may not have equivalent efficacy in nursing home residents. Our findings imply that differences in the humoral immune response may contribute to breakthrough infections, and suggest that consideration of the type of vaccine administered to older adults will have a positive impact on the generation of protective immunity.


Research Letters
Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents Q 1 Nursing home residents in Ontario, Canada, were prioritized for vaccination with mRNA vaccines from Moderna (mRNA-1273) or Pfizer (BNT163b2) in December 2020-January 2021, which significantly reduced the high morbidity and mortality due to COVID-19. 1 Nursing home residents often fail to mount robust responses to vaccinations 2 and recent reports of breakthrough infections, particularly from variants of concern, raise questions about whether vaccination regimens elicit a sufficient humoral immune response or if booster doses are warranted.

Methods
We examined SARS-CoV-2 antibody levels and neutralizing capacity in nursing home residents 3-5 months after 2 doses of mRNA-1273 or BNT163b2 vaccination as per recommended schedules. Residents were recruited from 8 sites nursing homes in Ontario, Canada, between March and July 2021. Antibody levels and neutralization capacity from a previously published convalescent cohort were used as a comparator. 3 All protocols were approved by the Hamilton Integrated Research Ethics Board, and informed consent was obtained.
Data are reported as a ratio of observed optical density to the determined assay cutoff optical density, with ratios above 1 considered positive. Neutralization capacity of these antibodies was assessed by cell culture assays with live SARS-CoV-2 virus, with data reported as geometric microneutralization titers at 50% (MNT 50 ), which ranged from below detection (MNT 50 ¼ 10) to MNT 50 ¼ 1280. 3 Antibody neutralization was measured against the wild-type strain of SARS-CoV-2 and the beta variant of concern (B.1.351). The beta variant was obtained through BEI Resources, National Institute of Allergy and Infectious Diseases, National Institutes of Health: SARS-Related Coronavirus 2, Isolate hCoV-19/ South Africa/KRISP-K005325/2020, NR-54009, contributed by Alex Sigal and Tulio de Oliveira.
Differences between antibody levels and neutralization in individuals that received mRNA-1273 or BNT163b2 were assessed by chi-square of independence (proportions), Kruskal-Wallis test (median), and Student t test (mean). All statistical analyses were conducted using SAS, version 9.4 (SAS Institute Inc, Cary, NC).

Results
The majority of residents (97.1%) produced antibodies to the spike (S) protein post vaccination; however, fewer residents (87.68%) produced immunoglobulin G (IgG) to the receptorbinding domain (RBD) domain (Table 1). Residents who received mRNA-1273 had higher median levels of IgG S protein [mRNA-1273 ¼ 2.9, interquartile range (IQR) 2.5-3.1] and IgG RBD (mRNA-1273 ¼ 2.5, IQR 1.7-3.0) than those who received BNT163b2 (IgG Spike: BNT163b2 ¼ 2.5, IQR 1.5-3.1, P ¼ .015; IgG RBD: BNT163b2 ¼ 1.5, IQR 0.7-2.6, P < .001). Participants who had been vaccinated with BNT163b2 had median values of both Ig Spike and RBD that were lower than the median values of a cohort of convalescent individuals. There were no differences between vaccine groups with respect to IgM/A to either S protein or RBD. No neutralizing antibodies were detected in w20% of residents to the wild-type virus (30/155; 19%) or beta variant (27/ 134; 20%). Residents that received BNT163b2 had an w4-fold reduction in neutralization to the wild-type strain and a w2fold reduction in neutralization to the beta variant relative to those who received mRNA-1273.